AUSENCO PLUMMETS ON PROFIT WARNING

AUSENCO PLUMMETS ON PROFIT WARNING

AUSENCO (ASX:AAX) shares have plummeted on a first half profit warning delivered by the mining services company today, which details the extraordinary $5 million cost of its redundancy program.

AAX shares were down 30.7 per cent today at $1.490 per unit, a huge drop from the $4.08 high achieved earlier this year.

The cost of the restructure will weight on the second quarter result, but it is expected to save $13 million in overhead costs in the second half of 2013 and between $20 million and $25 million annually from 2014.

The company says contract specific issues and a softer market will hurt the bottom line in the first half.

Unaudited first half 2013 performance is expected to deliver revenues of $255 million, underlying EBITDA between $15 and $16 million and underlying net profit after tax between $6 and $7 million.

Ausenco expects full year revenue to be between $564 million and $661 million and net profit after tax between $29 million and $41 million.

“Based on the lower first half performance and current lower business activity levels expected for the remainder of this year, the 2013 full year results will be below the current market consensus,” says the company.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Advertisement

Related Stories

Brisbane biotech to trial world-first COVID-19 immunotherapy treatment

Brisbane biotech to trial world-first COVID-19 immunotherapy treatment

Brisbane and Seattle-based biotechnology company Implicit Bioscie...

Federal Court finds Google misled consumers on data collection

Federal Court finds Google misled consumers on data collection

The Federal Court has found Google misled consumers about persona...

Redflow charging up ahead of next-gen battery launch

Redflow charging up ahead of next-gen battery launch

Redflow (ASX: RFX) is gearing up to launch the next generation of...

Mayne Pharma breakthrough as FDA approves new contraceptive with plant-based estrogen

Mayne Pharma breakthrough as FDA approves new contraceptive with plant-based estrogen

A bet made by Mayne Pharma (ASX: MYX) in 2019 has paid off today ...